Curasight announced an accelerated strategy for its theranostics platforn this morning, with the purpose of advancing forward in several cancer indications. The strategy involves a coming ph I/IIa basket trial including five different cancer indications, where both uTRACE and uTREAT will be combined in the study. First patient expected to be dosed in the beginning of 2025 with efficacy data in 2025.

Link to the analysis